GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codiak BioSciences Inc (OTCPK:CDAKQ) » Definitions » Enterprise Value

Codiak BioSciences (Codiak BioSciences) Enterprise Value : $9.57 Mil (As of May. 25, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Codiak BioSciences Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Codiak BioSciences's Enterprise Value is $9.57 Mil. Codiak BioSciences's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 was $-14.81 Mil. Therefore, Codiak BioSciences's EV-to-EBIT ratio for today is -0.65.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Codiak BioSciences's Enterprise Value is $9.57 Mil. Codiak BioSciences's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 was $-9.41 Mil. Therefore, Codiak BioSciences's EV-to-EBITDA ratio for today is -1.02.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Codiak BioSciences's Enterprise Value is $9.57 Mil. Codiak BioSciences's Revenue for the trailing twelve months (TTM) ended in Sep. 2022 was $33.57 Mil. Therefore, Codiak BioSciences's EV-to-Revenue ratio for today is 0.29.


Codiak BioSciences Enterprise Value Historical Data

The historical data trend for Codiak BioSciences's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Codiak BioSciences Enterprise Value Chart

Codiak BioSciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21
Enterprise Value
- - 580.91 235.39

Codiak BioSciences Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 329.03 235.39 146.96 85.00 38.32

Competitive Comparison of Codiak BioSciences's Enterprise Value

For the Biotechnology subindustry, Codiak BioSciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Codiak BioSciences's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Codiak BioSciences's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Codiak BioSciences's Enterprise Value falls into.



Codiak BioSciences Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Codiak BioSciences's Enterprise Value for the fiscal year that ended in Dec. 2021 is calculated as

Codiak BioSciences's Enterprise Value for the quarter that ended in Sep. 2022 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Codiak BioSciences  (OTCPK:CDAKQ) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Codiak BioSciences's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=9.574/-14.807
=-0.65

Codiak BioSciences's current Enterprise Value is $9.57 Mil.
Codiak BioSciences's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.81 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Codiak BioSciences's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=9.574/-9.41
=-1.02

Codiak BioSciences's current Enterprise Value is $9.57 Mil.
Codiak BioSciences's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.41 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Codiak BioSciences's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=9.574/33.574
=0.29

Codiak BioSciences's current Enterprise Value is $9.57 Mil.
Codiak BioSciences's Revenue for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $33.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Codiak BioSciences Enterprise Value Related Terms

Thank you for viewing the detailed overview of Codiak BioSciences's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Codiak BioSciences (Codiak BioSciences) Business Description

Traded in Other Exchanges
N/A
Address
35 Cambridge Park Drive, Suite 500, Cambridge, MA, USA, 02140
Codiak BioSciences Inc is a development-stage biopharmaceutical company focused on the development of exosome-based therapeutics for the treatment of a wide spectrum of diseases with high unmet medical need. The company have utilized engEx Platform to generate a pipeline of engineered exosomes, aimed at treating a broad range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease, infectious disease and rare disease.
Executives
Yalonda Howze officer: See Remarks C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Sriram Sathyanarayanan officer: Chief Scientific Officer C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Nicole Barna officer: See Remarks C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Douglas E Williams director, officer: President & CEO C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Linda Bain officer: Chief Financial Officer C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Konstantin Konstantinov officer: See Remarks C/O CODIAK BIOSCIENCES, INC., 500 TECHNOLOGY SQUARE, 9TH FLOOR, CAMBRIDGE MA 02139
Arch Venture Fund Viii Overage, L.p. 10 percent owner C/O ARCH VENTURE PARTNERS VIII, LLC, 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
David J Mauro officer: Chief Medical Officer 36 TERRELL DRIVE, WASHINGTON CROSS PA 18977
Arundathy N. Pandite director 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Benny Sorensen officer: See Remarks C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Anne-virginie Eggimann director C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Jennifer J. Wheler officer: Chief Medical Officer C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Briggs Morrison director C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Alaska Permanent Fund Corp 10 percent owner 801 WEST 10TH STREET, SUITE 302, JUNEAU AK 99801
Flagship Ventures Fund V, L.p. 10 percent owner ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142